HHEX and GM2 gangliosidosis: The studies described above led to expanded access (13) or Phase I/II clinical trials in children with GM2 gangliosidosis using AAV vectors expressing the Hex α and β subunits delivered to the thalamus and CSF or to the CSF alone (ClinicalTrials.gov Identifiers NCT04669535, NCT04798235).